Boehringer Ingelheim Begins Clinical Development of FirstInClass Treatment for Fibrotic Diseases
Boehringer Ingelheim announced today that it has launched clinical development of its firstinclass IL11 inhibitor antibody BI 765423 with a Phase 1 study NCT05658107 to assess the safety tolerability and pharmacokinetics in healthy volunteers.
Source: businesswireindia.com